Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells

• Published in: PloS one Vol. 9; no. 1; p. e85771
• Main Authors: Chen, Li, Ye, Hui-Lan, Zhang, Guo, Yao, Wen-Min, Chen, Xing-Zhou, Zhang, Fa-Can, Liang, Gang
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 21.01.2014; Public Library of Science (PLoS)
• Subjects: Analysis; Animals; Anthracyclines; Anticancer properties; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Apoptosis - drug effects; Augmentation; Autophagy - drug effects; Biology; Cancer therapies; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - ultrastructure; Catechin; Catechin - analogs & derivatives; Catechin - pharmacology; Cell death; Cell Line, Tumor; Cell Proliferation - drug effects; Chemistry; Chemotherapy; Chloroquine; Combined treatment; Dose-Response Relationship, Drug; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - pharmacology; Drug Synergism; Electron microscopy; Epigallocatechin gallate; Epigallocatechin-3-gallate; Fluorescence; Green tea; Growth inhibition; Hepatocellular carcinoma; Hepatoma; Humans; Immunohistochemistry; Inhibition; Kinases; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Liver Neoplasms - ultrastructure; Medicine; Mice; Mice, Nude; Mortality; Phagocytosis; Rapamycin; Ribonucleic acid; RNA; RNA-mediated interference; Signaling; siRNA; Synergistic effect; Tea; Up-Regulation - drug effects; Western blotting; Xenograft Model Antitumor Assays; Xenografts
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0085771

(-)-Epigallocatechin-3-O-gallate(EGCG), the highest catechins from green tea, has promisingly been found to sensitize the efficacy of several chemotherapy agents like doxorubicin (DOX) in hepatocellular carcinoma (HCC) treatment. However, the detailed mechanisms by which EGCG augments the chemotherapeutic efficacy remain unclear. Herein, this study was designed to determine the synergistic impacts of EGCG and DOX on hepatoma cells and particularly to reveal whether the autophagic flux is involved in this combination strategy for the HCC. Electron microscopy and fluorescent microscopy confirmed that DOX significantly increased autophagic vesicles in hepatoma Hep3B cells. Western blot and trypan blue assay showed that the increasing autophagy flux by DOX impaired about 45% of DOX-induced cell death in these cells. Conversely, both qRT-PCR and western blotting showed that EGCG played dose-dependently inhibitory role in autophagy signaling, and that markedly promoted cellular growth inhibition. Amazingly, the combined treatment caused a synergistic effect with 40 to 60% increment on cell death and about 45% augmentation on apoptosis versus monotherapy pattern. The DOX-induced autophagy was abolished by this combination therapy. Rapamycin, an autophagic agonist, substantially impaired the anticancer effect of either DOX or combination with EGCG treatment. On the other hand, using small interference RNA targeting chloroquine autophagy-related gene Atg5 and beclin1 to inhibit autophagy signal, hepatoma cell death was dramatically enhanced. Furthermore, in the established subcutaneous Hep3B cells xenograft tumor model, about 25% reduction in tumor growth as well as 50% increment of apoptotic cells were found in combination therapy compared with DOX alone. In addition, immunohistochemistry analysis indicated that the suppressed tendency of autophagic hallmark microtubule-associated protein light chain 3 (LC3) expressions was consistent with thus combined usage in vitro. Taken together, the current study suggested that EGCG emerges as a chemotherapeutic augmenter and synergistically enhances DOX anticancer effects involving autophagy inhibition in HCC.